Transcode Therapeutics, Inc. Net Income Loss

Quick Answer

Transcode Therapeutics, Inc. reported Net Income Loss of -$16.75 million for the year ending 2024.

  • Transcode Therapeutics, Inc. showed an increase of +9.7% in Net Income Loss from 2023 to 2024.
  • This data is from Transcode Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
  • XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2020 to 2024), Transcode Therapeutics, Inc.'s Net Income Loss has declined by 614.8%.
  • Historical annual values: Fiscal year 2024: -$16.75 million | Fiscal year 2023: -$18.55 million | Fiscal year 2022: -$17.56 million | Fiscal year 2021: -$6.84 million | Fiscal year 2020: -$2.34 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: